PharmaCorp Rx Inc. (PCRX.V) saw a notable gain of 4.00% in its stock price during the last trading session, closing at CA$0.52.
In a positive turn for investors, PharmaCorp Rx Inc. has experienced a significant uptick in its stock value, thanks to recent corporate developments that signal growth and boost investor confidence. The company's latest financial moves and strategic acquisitions seem to be resonating well with the market.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
PharmaCorp Rx Inc.
PCRX.V
PCRX.V
PharmaCorp Rx Inc.
WealthAwesomeMarket cap
$87.04M
52W high
$0.58
52W low
$0.40
1W change
+1.01%
Beta
-4.27
Analyst Price Targets
Based on analyst covering PCRX
Wall Street analysts forecast PCRX stock price to rise 33.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.67
+33.3% Upside
Current Price
C$0.50
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PCRX's historical volatility
30-Day Vol
75.2%
Annualized
90-Day Vol
61.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.60
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.53 | C$0.41 โ C$0.69 |
| 60 trading days | C$0.56 | C$0.39 โ C$0.81 |
| 90 trading days | C$0.60 | C$0.38 โ C$0.94 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: PharmaCorp's recent capital raise and acquisition strategy may position the company for future growth, making it a stock to watch for potential investors.
Stock Gains 4.00% in One Day
PharmaCorp's market capitalization now stands at CA$87 million, reflecting growing investor interest following recent corporate actions.
Bull case
The successful completion of a C$11.5 million bought deal public offering strengthens PharmaCorp's financial position. This funding allows the company to invest in growth initiatives, including acquisitions and expanding its pharmacy operations.
Bear case
Despite the positive market reaction, investors should stay cautious. PharmaCorp's current profit margin is negative, highlighting ongoing profitability challenges that could impact future performance.
Recent Developments Fueling Growth
PharmaCorp's stock surge can be traced back to its recent announcement of a C$11.5 million bought deal public offering, which was successfully closed by issuing 22,549,200 units at CA$0.51 each. This capital infusion is expected to enhance the company's operational capabilities and support further acquisitions, such as the recent purchase of a pharmacy in Morrisburg, Ontario for $8.2 million.
Market Response and Future Outlook
The market's positive response to PharmaCorp's strategic moves reflects growing confidence among investors. With the company's market cap now at CA$87 million, stakeholders are closely watching how these developments will translate into financial performance in the coming quarters. However, investors should keep an eye on the company's profit margins, which currently remain in negative territory.
Advertisement
